<DOC>
	<DOC>NCT01164488</DOC>
	<brief_summary>This non-randomized, open-label study will evaluate the interaction of RO5190591(danoprevir)/ritonavir with and without ketoconazole and the safety and tolerability in healthy volunteers. Participants will be administered repeated daily doses of ketoconazole alone, RO5190591/ritonavir, and RO5190591/ritonavir plus ketoconazole. The anticipated time on study treatment is 25 days.</brief_summary>
	<brief_title>A Study of RO5190591 (Danoprevir) in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Adult healthy volunteers, aged 1864 years, inclusively Weight &gt;/=50.0 kg Body Mass Index (BMI) 18.032.0 kg/m2 Ability and willingness to abstain from alcohol, xanthinecontaining beverages or food (coffee, tea, cola, chocolate, "energy drinks") from 48 hours prior to entry in the clinical study center until discharge Ability and willingness to abstain from grapefruit or grapefruit juice, star fruit, and Seville oranges from 7 days prior to entry in the clinical study center until discharge Medical history without major recent or ongoing pathology Pregnant or lactating women and male partners of women who are pregnant or lactating Sustained supine systolic blood pressure &gt;140 or &lt;90 mmHG and supine diastolic blood pressure &gt;90 or &lt;50 mmHG at Screening or Day 1 Resting heart rate &gt;100 or &lt;45 beats per minute at Screening or Day 1 Any history of clinically significant cardiovascular or cerebrovascular disease Positive drug test result at screening or each admission Donation or loss of blood over 450 ml (1 pint) within 60 days prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>